Brina, Daniela
Ponzoni, Adele
Troiani, Martina
Calì, Bianca
Pasquini, Emiliano
Attanasio, Giuseppe
Mosole, Simone
Mirenda, Michela
D’Ambrosio, Mariantonietta
Colucci, Manuel
Guccini, Ilaria
Revandkar, Ajinkya
Alajati, Abdullah
Tebaldi, Toma http://orcid.org/0000-0002-0625-1631
Donzel, Deborah
Lauria, Fabio
Parhizgari, Nahjme
Valdata, Aurora
Maddalena, Martino
Calcinotto, Arianna http://orcid.org/0000-0003-1746-6424
Bolis, Marco http://orcid.org/0000-0003-4377-5079
Rinaldi, Andrea
Barry, Simon http://orcid.org/0000-0002-8511-0588
Rüschoff, Jan Hendrik
Sabbadin, Marianna
Sumanasuriya, Semini
Crespo, Mateus
Sharp, Adam
Yuan, Wei
Grinu, Mathew
Boyle, Alexandra
Miller, Cynthia
Trotman, Lloyd http://orcid.org/0000-0002-4794-1559
Delaleu, Nicolas
Fassan, Matteo
Moch, Holger http://orcid.org/0000-0002-7986-2839
Viero, Gabriella http://orcid.org/0000-0002-6755-285X
de Bono, Johann http://orcid.org/0000-0002-2034-595X
Alimonti, Andrea http://orcid.org/0000-0002-9362-2313
Funding for this research was provided by:
Prostate Cancer Foundation (19CHAL08)
Article History
Received: 9 May 2022
Accepted: 13 June 2023
First Online: 17 July 2023
Competing interests
: S.B. is affiliated with IMED Oncology AstraZeneca, Li Ka Shing Centre, Cambridge, UK and provided the AZD5069 compound. Johann de Bono has served on Advisory Boards for Roche and AstraZeneca and he is an employee of the ICR, which has received funding or other support for his research work from AstraZeneca and which has a commercial interest in PI3K/AKT pathway inhibitors (no personal income). Johann de Bono and Andrea Alimonti are principal investigators of the NCT03177187 trial which was partially supported by AstraZeneca and Astellas Pharma. The remaining authors declare no competing interests.